ORIGINAL ARTICLESLack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics
REFERENCES (24)
- et al.
Aspirin-sensitive rhinosinusitis/asthma: spectrum of adverse reactions to aspirin
J Allergy Clin Immunol
(1983) - et al.
Aspirin intolerance in asthma-detection by challenge
J Allergy Clin Immunol
(1972) - et al.
Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy
J Allergy Clin Immunol
(1996) - et al.
Aspirin desensitization in aspirin sensitive asthmatic patients: clinical manifestations and characterization of the refractory period
J Allergy Clin Immunol
(1982) - et al.
Urinary leukotriene E4 levels during early and late asthmatic responses
J Allergy Clin Immunol
(1990) - et al.
Sensitivity to aspirin and nonsteroidal antiinflammatory drugs
Oral challenges to detect aspirin and sulfite sensitivity in asthma
N E Reg Allergy Proc
(1988)Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation
Science
(1983)The role and contribution of leukotrienes in asthma
Ann Allergy Asthma Immunol
(1998)- et al.
Treatment of asthma with drugs modifying the leukotriene pathway
N Engl J Med
(1999)
The role of leukotriene modifiers in the treatment of asthma
Am J Respir Crit Care Med
Antileukotrienes in the treatment of asthma
Ann Intern Med
Cited by (45)
The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology
2021, Journal of Allergy and Clinical ImmunologyCitation Excerpt :Few trials have attempted to determine differences of an LTRA as compared with a 5-LO inhibitor in the attenuation of lower airway symptoms. In an observational study, an LTRA was found to be superior to a 5-LO inhibitor (zileuton),88 and another small study of 6 subjects found that zileuton had minimal effects in 4 of 6 subjects.89 There is also limited data on the effects of combining a 5-LO inhibitor with an LTRA before desensitization.
Lipid Mediators in Aspirin-Exacerbated Respiratory Disease
2016, Immunology and Allergy Clinics of North AmericaCitation Excerpt :Although zileuton was promising given its ability to reduce the production of CysLTs as well as LTB4, its clinical utility has been variable, likely because of its failure to completely block LT formation. Other studies have shown that although zileuton can increase the threshold dose of aspirin required to provoke a reaction, the effect of 5-LO inhibition can be overcome.67 The widespread use of zileuton has been complicated by hepatotoxicity and the need for frequent dosing.
Performing Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease
2016, Immunology and Allergy Clinics of North AmericaCitation Excerpt :Leukotriene receptor blockers montelukast and zafirlukast have been shown to not completely mask the upper respiratory symptoms during oral NSAID challenge3,6; they are, thus, the preferred LTMDs to use. Zileuton, a 5-lipoxygenase inhibitor, has not been studied as rigorously in this context; but one small study showed that it did not mask symptoms completely in 6 out of 6 patients.7 The potential disadvantage of using zileuton as pretreatment is a false-negative result.
Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease
2015, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :Double-blinded, placebo-controlled trials showed that zileuton improved pulmonary function, diminished nasal dysfunction, and inhibited aspirin-induced bronchoconstriction.18,19 The finding that zileuton provides both upper and lower respiratory tract effects is promising.20,21 Although we are unable to generalize worldwide, in our practice, cost and insurance coverage is a major limiting factor in the accessibility to zileuton.
Allergy diagnostic testing: An updated practice parameter
2008, Annals of Allergy, Asthma and ImmunologySafety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease
2006, Annals of Allergy, Asthma and Immunology
Intramural Grant (#97-20) from Academic Affairs, Scripps Clinic and GCRC of Scripps Clinic, Scripps Green Hospital, The Scripps Research Institute (Grant #M01RR00833).